Makati Surgicenter

Peregrine Eye and Laser Institute

Ocular Hypertension

Open-Angle Glaucoma

Edema

Keratoconjunctivitis Sicca

Dry Eye Syndromes

Hypertension

Macular Edema

Macular Degeneration

Glaucoma

Bimatoprost

DE-122

AGN-195263

Dexamethasone

AbbVie

Allergan

Santen

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Peregrine Eye and Laser Institute | Makati Surgicenter

Site insights

Work at this site?

Active trials

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (MAIA)

Trial sponsors